RxDoctor Payments Data

Celia McCauley-Wittl

Nurse Practitioner · Roanoke, VANPI 1124666078

Payments from drug & device makers

$1,715in general payments, 2019–2025

Across 52 payments — averaging $32.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$498
  • Novo Nordisk$244
  • Neurocrine Biosciences, Inc.$148
  • E.r. Squibb & Sons, L.L.C.$138
  • Xeris Pharmaceuticals, Inc.$135
  • Axsome Therapeutics, Inc.$122
  • plus $429 from 8 others

What the payments were for

  • Food & beverage$1,715100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,715 in reported general payments places this provider in the 85th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$12,071
Medicare patients
16
Services billed
114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Risperdal ConstaRisperidone Microspheres39$49,115
Abilify MaintenaAripiprazole11$31,206
Ramelteon11$1,351
Naltrexone Hcl31$1,130
Haloperidol Decanoate13$945
Quetiapine Fumarate ErQuetiapine Fumarate12$595
Risperidone48$580
Prazosin Hcl26$509
Duloxetine Hcl32$458
Aripiprazole31$443
Benztropine Mesylate40$440
Lurasidone Hcl13$394
Buspirone Hcl26$376
Trazodone Hcl49$359
Haloperidol13$316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonRisperdal Consta$104$49,11539 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$498$31,20611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Roanoke

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →